Vimian Group AB (VIMIAN) Fair Value & Analysis
Healthcare · SE · Market cap 17.8B SEK (≈ $1.9B) · ISIN SE0015961982
What is Vimian Group AB really worth?
A solid business, but trading 76% above our fair value of kr 19.64.
Strengths
Risks
Fair value as of: Aug 14, 2026
From 24 valuation models · updated 21 days ago
Fair value updated Aug 14, 2026, revised from kr 14.41 to kr 19.64 (+36.3%) since Jul 19, 2026. Share price −1.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 25.64). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (kr 13.64 to kr 25.64) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.
How to read this chart
60‑month range kr 20.08 – kr 117.16 · fair‑value band kr 13.64 – kr 25.64 · the kr 34.60 price screens above the kr 19.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 14, 2026.
Analysis
Vimian Group AB (VIMIAN) currently trades at kr 34.60, while our model-based Fair Value estimate is kr 19.64, implying the stock looks roughly 76.2% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of kr 50.37 per share, and 13 of the 24 models we run sit above the kr 34.60 price. Bear case: the Asset-Based group reads lowest at kr 13.34, and 11 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Vimian Group AB generated revenue of 434M SEK at a net margin of 8.5%. Revenue grew 7.9% year over year. It earns a return on equity of 5.3%. Net debt stands at 184M SEK. Fundamentals as of Aug 14, 2026
Our scenario range runs from kr 13.64 (bear case) to kr 25.64 (bull case); at kr 34.60, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 43% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −54% fair-value upside, at −43%, VIMIAN screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly kr 0.5278 per share, which is 2.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (kr 50.37) versus Asset-Based (kr 13.34). Highest evidence: EPV (74).
Notify me when VIMIAN reaches fair value
Put VIMIAN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services.
Full company description
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vimian Group AB reported revenue of €425M in FY2025 versus €173M in FY2021, a compound +25.1%/yr. Reported net income was €31.3M in FY2025, compounding +47.6%/yr from FY2021.
VIMIAN screens 76% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 140 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 30/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | −51% |
| Danaher Corporation DHR | $215.68 | $103.88 | −52% |
| WuXi AppTec Co 2359 | HK$189.30 | HK$150.16 | −21% |
| Lonza Group LONN | CHF 576.60 | CHF 259.80 | −55% |
| IDEXX Laboratories, Inc IDXX | $556.69 | $255.77 | −54% |
| Agilent Technologies, Inc A | $149.93 | $61.53 | −59% |
| Waters Corporation WAT | $416.15 | $121.96 | −71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | −44% |
| Illumina, Inc ILMN | $215.59 | $95.51 | −56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | −57% |
Compare Vimian Group AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Vimian Group AB (VIMIAN) overvalued or undervalued?
What is the fair value of VIMIAN?
What is the quality score of VIMIAN?
What is the revenue of Vimian Group AB (VIMIAN)?
What is the net profit margin of VIMIAN?
Watch Vimian Group AB in the live analysis
One click puts Vimian Group AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.